Indications and efficacy of talazoparib/Tazena in breast cancer

Talazoparib is a highly effective poly(ADP-ribose) polymerase (PARP) inhibitor. It mainly blocks the DNA single-strand repair pathway and induces double-strand breaks in tumor cells during the replication process, ultimately leading to cell death. This mechanism is particularly effective in tumors with BRCA1/2 gene mutations, because these cells have lost part of their DNA repair ability and are therefore more sensitive to PARP inhibitors.

In the field of breast cancer, talazoparib's core indication is for the treatment of adult patients with deleterious or potentially harmful germline BRCA mutations (gBRCAm) and HER2-negative locally advanced or metastatic breast cancer. These patients usually have limited treatment options, and talazoparib provides them with a new approach to targeted precision therapy. Compared with traditional chemotherapy, talazoparib can improve treatment efficiency while reducing some toxic side effects, thereby improving patients' quality of life.

In clinical research and practice, talazoparib has shown relatively durable remission effects and disease control capabilities. International guidelines have clearly recommended this drug as an important treatment option for BRCA-mutated breast cancer, which provides clinicians with a basis for individualized treatment plans. Its oral administration method also makes it more convenient for patients to use and is conducive to long-term adherence to treatment.

In addition to breast cancer, talazoparib is also making progress in prostate cancer. In combination with enzalutamide, it is approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene mutations. This combination program has received widespread attention in the international academic community and is believed to be able to further delay disease progression and open up new treatment ideas for patients with advanced prostate cancer.

In general, talazoparib, as a new generation ofPARP inhibitor, its breast cancer indication has been recognized by international and domestic regulatory agencies and has gradually been incorporated into clinical practice.

Reference materials:https://www.talzenna.com/